

26 April 2023

Markets Announcement Office ASX Limited 20 Bridge Street Sydney, NSW 2000

EZZ Life Science Holdings Limited (ASX: EZZ) (Company) Change of Director Interest Notice

EZZ Life Science Holdings Limited (EZZ) refers to the attached Change of Director Interest Notice for Mr Ivan Oshry (**Director**) and advises the following:

- 1. The on-market purchase of shares was made on 18 April 2023 by Ms Terry Oshry (the Director's spouse);
- The trade was inadvertently not made within the Trading Windows specified in the Company's Securities Trading Policy, and accordingly was a purchase transaction during a Prohibited Period;
- 3. Accordingly, prior written consent was not requested to allow the trade to proceed during the Prohibited Period due to an oversight by the Director;
- 4. Pursuant to the Company's Securities Trading Policy, directors are required to provide written notice of their intention to trade directly or indirectly in the Company's securities to the Relevant Officer (being the Chairperson of the Board or, in the case of an application from the Chairperson, the Chair of the Audit and Risk Committee) and the Company Secretary;
- 5. After dealing, a director must confirm in writing to the Company Secretary, within 3 days that the dealing in the shares has occurred, the number of the shares affected and the relevant parties to the dealing;
- 6. The Company is of the view that the abovementioned oversight is a non-material and isolated incident and its current arrangements in relation to its Securities Trading Policy are adequate for compliance with listing rule 3.19B.
- 7. To the extent necessary, the Company has excused the non-compliance and approved the purchase of shares.

Natalie Climo Company Secretary

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EZZ Life Science Holdings Limited
ABN	83 608 363 604

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ivan Oshry
Date of last notice	8 March 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Terry Oshry (Ms Oshry is the director's spouse)	
Date of change	18 April 2023	
No. of securities held prior to change	10,000 Fully paid ordinary shares	
Class	Fully paid ordinary shares	
Number acquired	11,000	
Number disposed	-	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.42	

⁺ See chapter 19 for defined terms.

No. of securities held after change	Direct 10,000 Fully paid ordinary shares	
	Indirect 11,000 Fully paid ordinary shares held by Terry Oshry	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	On market trade	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	Yes
above traded during a ⁺ closed period where prior written	
clearance was required?	

⁺ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was	N/A
this provided?	
26 April 2023	·

+ See chapter 19 for defined terms.